Document is current
Any future updates will be listed below
-
Authors
Varghese, Anna M. https://orcid.org/0000-0001-5426-0885
Perry, Maria A. https://orcid.org/0000-0002-8789-251X
Chou, Joanne F.
Nandakumar, Subhiksha
Muldoon, Daniel https://orcid.org/0000-0001-7936-4365
Erakky, Amanda
Zucker, Amanda https://orcid.org/0000-0002-9283-7072
Fong, Christopher
Mehine, Miika https://orcid.org/0000-0003-0443-0625
Nguyen, Bastien
Basturk, Olca https://orcid.org/0000-0003-2747-1366
Balogun, Fiyinfolu https://orcid.org/0000-0003-4703-1560
Kelsen, David P.
Brannon, A. Rose https://orcid.org/0000-0003-4610-0149
Mandelker, Diana https://orcid.org/0000-0003-4154-0567
Vakiani, Efsevia https://orcid.org/0000-0003-0227-3523
Park, Wungki https://orcid.org/0000-0002-8006-3102
Yu, Kenneth H.
Stadler, Zsofia K. https://orcid.org/0000-0002-6985-2864
Schattner, Mark A.
Jarnagin, William R.
Wei, Alice C. https://orcid.org/0000-0002-2505-959X
Chakravarty, Debyani https://orcid.org/0000-0001-8629-5732
Capanu, Marinela
Schultz, Nikolaus https://orcid.org/0000-0002-0131-4904
Berger, Michael F. https://orcid.org/0000-0003-3882-5000
Iacobuzio-Donahue, Christine A. https://orcid.org/0000-0002-4672-3023
Bandlamudi, Chaitanya https://orcid.org/0000-0003-1108-4919
O’Reilly, Eileen M. https://orcid.org/0000-0002-8076-9199
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA008748, CA257881-01A1, P30 CA008748, P50 CA257881-01A1, CA008748, CA008748, CA008748, CA257881-01A1, CA008748, CA257881-01A1, CA008748)
- License Information
-
More Information
Article History
Received: 26 February 2024
Accepted: 17 October 2024
First Online: 3 January 2025
Change Date: 21 January 2025
Change Type: Update
Change Details: In the version of the article initially published, the peer review statement was incorrect and has now been amended to “<i>Nature Medicine</i> thanks Mariano Ponz-Sarvise, Channing Der and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.” Additionally, the y-axis label of Extended Data Fig. 4e read “OS Probability” and has now been amended to read “PFS Probability.” The changes are made in the HTML and PDF versions of the article.
Competing interests
: M.A.P. declares stock ownership in Amgen. A.M.V. declares consulting activity from AstraZeneca (spouse), Eli Lilly (spouse) and Paige AI (spouse), and intellectual property rights (SOPHiA Genetics) (spouse). B.N. is a current employee of Eli Lilly and Company. D. Mandelker declares consulting fees from AstraZeneca. F.B. receives research support from BMS. D.P.K. receives funding from the Thompson Family Foundation and Applebaum Foundation and is a consultant at Merck, BMS, BeiGene, Lilly, Abbvie, Incyte, Janssen, Listen and TG Therapeutics. A.R.B. declares stock ownership in Johnson & Johnson and intellectual property rights in SOPHiA Genetics. W.P. receives research funding from Merck, Astellas, Miracogen, Amgen and Revolution Medicines, is a consultancy/advisory board member for Astellas, EXACT Therapeutics, Innovent Biologics and Regeneron and has received honoraria for CME: American Physician Institute, Integrity. M.F.B. declares consulting activity from AstraZeneca, Eli Lilly and Paige AI and intellectual property rights (SOPHiA Genetics). E.M.O. receives research funding from Agenus, Amgen, Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI and Digestive Care, consulting/DSMB role at Arcus, Ability Pharma, Alligator, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicine, Merus, Moma Therapeutics and Tango; Agios (spouse), Genentech-Roche (spouse), Eisai (spouse) Servier (spouse). The remaining authors declare no competing interests.
